Pharma/fine chemicals roundup—1 October 2013
1:05 AM MDT | October 1, 2013 | By DEEPTI RAMESH
New CEO for Bayer HealthCare
Bayer says that Olivier Brandicourt has been appointed chairman of the board of management of Bayer HealthCare (Leverkusen) and member of the Bayer executive council, effective 1 November. Jörg Reinhardt, the former head of Bayer HealthCare, left the company earlier this year. Wolfgang Plischke has led Bayer HealthCare since March on an interim basis, in addition to his existing duties as a Bayer board member. Brandicourt has 25 years of international experience in the pharmaceutical industry, including executive responsibilities in France, the United States, Canada, and the United Kingdom, Bayer says. He has been a member of the executive leadership team of Pfizer (New York) for the past three years.
Solvay to build Southeast Asia's first sodium bicarbonate plant
Solvay announced plans to build its first sodium bicarbonate production plant in Asia/Pacific. The plant will be constructed at Solvay’s existing production site at Map Ta Phut and will be the first sodium bicarbonate production facility to be built by any company in Southeast Asia. Solvay will invest €20 million ($27.1 million) to build the plant, which will have capacity for 100,000 m.t./year of sodium bicarbonate, with start-up scheduled for the first half of 2015.
The new plant will supply “high-quality product to high-end markets,” mainly health care and food, says Pascal Juéry, president/essential chemicals at Solvay. “We believe the time is right to target these specific market segments in Asia, where standards of living are increasing and there is a drive for food safety, as well as stricter requirements in the pharmaceuticals market.”
Servier to acquire remaining stake in Egis Pharmaceuticals
Servier Group (Paris), a privately-held research-led pharmaceutical group, has made a voluntary public offer to purchase all outstanding shares in its affiliate Egis Pharmaceuticals (Budapest) for Hungarian forint 28,000/share ($127/share) in cash. Servier has owned a 51% stake in Egis since 1995. Egis is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe and CIS countries, and the company focuses on research, development and commercialization of pharmaceuticals and active pharmaceutical ingredients (APIs) for the treatment of cardiovascular, central nervous system, respiratory and digestive system disorders.
Merck KGaA announces multiple management changes in its pharmaceutical businesses
Merck KGaA (Darmstadt, Germany) announced multiple management and organizational changes in its pharmaceutical businesses. Belén Garijo, currently COO at Merck Serono (Geneva), the biopharmaceutical division of Merck KGaA, has been appointed president and CEO of Merck Serono, effective 1 October. She will succeed Stefan Oschmann, who, as member of the executive board and head/pharmaceuticals at Merck, will focus on further developing the Merck Serono and consumer health divisions as well as the allergopharma and biosimilars units. All four entities will report to Oschmann. Merck Serono, which generated total revenues of €6.4 billion ($8.64 billion) in 2012, is the largest division of Merck KGaA. Merck KGaA's overall pharmaceutical businesses accounted for about 60% of total revenues and 58% of Ebitda before one-time items last year, the company says.
AMRI awarded development and manufacturing contract by UK government
Albany Molecular Research Inc. (AMRI; Albany, NY) says that its wholly owned Albany Molecular Research UK (Holywell, UK) subsidiary has been awarded a seven-year contract for the development and manufacture of an active ingredient under clinical evaluation. The contract was awarded by the Defense Science and Technology Laboratory (Salisbury, UK) acting on behalf of the UK secretary of state for defense, the Department of National Defence of Canada (Ottawa), and minister of defense of the Netherlands. AMRI will initially work on the development and scale-up of the investigational drug and, subsequently, the manufacture and supply for use during phase-one clinical trials. If the trials are successful, AMRI will be in a strong position to become the commercial manufacturer of the product for distribution to the government partners of this contract, including the United Kingdom, Netherlands, and Canada, AMRI says.
Connect with IHS Chemical Week
Our related sites